Vadodara - Alembic Pharmaceuticals Limited reported its consolidated financial results for the quarter ending 30 1 h June, 2022

Mr. Shaunak Amin, Managing Director, Alembic Pharmaceuticals Limited said 'India Branded Business continues to deliver robust numbers in 01. India Business . will witness market outperforming growth across most of the products and therapy areas in current year.'

Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said 'It was tough quarter with significant price erosion in the US market, we also charged off a non-recurring expense of Rs. 115 Cr.'

Profit before tax for the quarter is Rs. 47 Cr. before charging off the above nonrecurring expense.

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures. and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5500+ are well recognized by doctors and patients.

Information about the company can be found at www.alembicpharmaceuticals.com

Contact:

Mitanshu Shah

Phone: +91 265 - 6637630

Email: mitanshu.shah@alembic.co.in

(C) 2022 Electronic News Publishing, source ENP Newswire